
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. is poised for significant revenue growth, projecting total revenues to reach $373 million by 2032, an increase from the previous estimate of $339 million, largely attributed to its entry into the Medicaid Drug Rebate Program. The company has also raised its product revenue forecast for 2025 to a range of $94 million to $98 million, marking a substantial increase of 159% at the mid-point from $37 million in 2024. This positive trajectory is further supported by management's updated revenue guidance, reflecting confidence in the firm’s oncology-focused strategies and operational effectiveness.
Bears say
Delcath Systems Inc faces a challenging outlook primarily attributed to its reliance on a single product and its performance in a competitive oncology market. The lack of diversification in its product offerings and the ongoing difficulty in expanding market penetration may hinder revenue growth and profitability. Additionally, the upward revision of the 12-month price target suggests fluctuating confidence in the company's financial stability amidst these operational challenges.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares